Micrograph of a diffuse large B cell lymphoma. Credit: Nephron / commons.wikimedia.org.

The European Medicines Agency (EMA) has validated AbbVie’s marketing authorization application (MAA) for epcoritamab (DuoBody-CD3xCD20) to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients following two or more lines of systemic therapy.

Simultaneously, Genmab has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the investigational subcutaneous IgG1-bispecific antibody to treat R/R large B-cell lymphoma (LBCL) patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Both the regulatory applications are supported by data obtained from the LBCL arm of the multi-centre, open-label, Phase II EPCORE NHL-1 trial.

The study was designed for assessing the antibody’s initial efficacy and safety in relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin’s lymphoma (NHL), including DLBCL adult patients.

AbbVie global oncology development vice-president and head Mohamed Zaki said: “The regulatory submissions for epcoritamab exemplify our pursuit to deliver innovative care for people living with large B-cell lymphoma and diffuse large B-cell lymphoma who have limited treatment options.

See Also:

“This achievement represents an initial step in our commitment to scientific research and providing an important treatment option with the potential to become a core therapy for people living with B-cell malignancies such as LBCL and DLBCL.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Being co-developed by AbbVie and Genmab, epcoritamab has been designed to bind to CD3 on T-cells and CD20 on B-cells simultaneously.

It also induces T-cell-mediated killing of CD20+ cells.

AbbVie and Genmab share the commercial responsibilities for epcoritamab in the US and Japan, while AbbVie holds the rights to commercialise the antibody across the world.

Both firms are also evaluating the antibody in a Phase III randomised, open-label trial as a monotherapy for R/R DLBCL patients.